Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Active IgG4-RD
NCT07068165Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenalidomide in IgG4-related disease (IgG4-RD), sponsored by Peking Union Medical College Hospital. Started Jul 2025; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07068165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068165.